TNSAM Addiction Medicine. Data source: Tennessee Department of Health, Office of Health Statistics, Death Statistical System. Overdose deaths were defined.

Slides:



Advertisements
Similar presentations
Pharmacy Services Agreements Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 5/08/06.
Advertisements

Controlled Substance Monitoring Database Prescription Drug Abuse Prevention Conference September 19, 2014 Andrew Holt, PharmD. Controlled Substance Monitoring.
MAPS Michigan Automated Prescription System. Exempt From Reporting Medications administered directly to patients. Dispensing of up to a 48 hour supply.
Preventing Prescription Drug Abuse: Laws and Legislation Hollie Hendrikson, MSc Policy Specialist, Health Program.
Innovative Approach of Managing High Risk Chronic Opioid Users in a Residency Practice Erin Inglis, MD a, Jessie Burch, PharmD b, Nida Awadallah, MD c,,
Rx for Drug-Seeking Patients in the ED The Monterey County Prescribe Safe Initiative 1.
Pain Management: a Regulatory Perspective William J. Schmidt, J.D. Senior Counsel, Investigations, Compliance & Enforcement Randy Beck Investigative Supervisor.
VIRGINIA PRESCRIPTION MONITORING PROGRAM C.A.R.E Presentation February 27, 2015 Ralph Orr Director, Virginia Prescription Monitoring Program.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Medical Director Jackson County Health and Human Services
MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.
Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.
Addressing the Substance Abuse Epidemic in Tennessee
Chronic Pain Initiative CCNC and Project Lazarus: Chronic Pain and Community Initiative.
Slide 1 Best Practices Working Group Chapter 244 Acts of 2012 Joint Policy Working Group Bureau of Health Care Safety and Quality Director Madeleine Biondolillo,
Richard Z Aramini, PharmD PGY-1 Pharmacy Practice Resident Bay Pines VA Healthcare Center.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
What are we doing in Southern Oregon? Concerns about opioid prescribing practices.
Opioid Use in Work-related Injuries Pacific Northwest Chapter - Association of Occupational Health Professionals (AOHP) January 4, 2011 Jaymie Mai, PharmD.
For Pain or Not for Pain: Methadone Madness
1 Alcohol and Substance Abuse Council of Jefferson County, Inc. 167 Polk Street, Suite 320 Watertown, New York Voice: ; Fax: ;
Department of Health and Vanderbilt University Chronic Pain Symposia
Department of Health and Vanderbilt University Chronic Pain Guidelines Symposium Elizabeth Lund, Executive Director, Board of Nursing Linda Johnson, APN.
2015 Tennessee Controlled Substances Monitoring Database Program D. Todd Bess, Pharm.D. Director Tennessee Controlled Substance Monitoring Database.
Powered by:. What is Physician’s Dispensing? Physician’s Dispensing is when a practice has the ability to fulfill patient prescriptions at the point of.
Texas State Board of Medical Examiners Bruce A. Levy, M.D., J.D.
Origin and Process of Utah Guidelines Anna Fondario, MPH Utah Department of Health Violence and Injury Prevention Program.
Opiate Management Douglas Keehn DO Adjunct Assistant Clinical Professor University Wisconsin Board Certified Anesthesia & Pain Management.
Pain Management: Narcotics, Implantable Therapies Maher Fattouh MD Adjunct Assistant Clinical Professor University Wisconsin Medical Director, Advanced.
Implementing a Urine Drug Screening Protocol to Teach Appropriate Opioid Prescribing in a Residency Practice STFM Annual Conference May 2, 2016 Nata Young,
Medicated Assisted Treatment (MAT) Terry R. Jones Director of Behavioral Health.
SOONERCARE PAIN MANAGEMENT PROGRAM. SOONERCARE PAIN MANAGEMENT PROGRAM The SoonerCare Pain Management Program is designed to equip SoonerCare providers.
Safe Prescribing of Opioids for the Management of Chronic Nonterminal Pain La Tanya Austin, PGY3.
Prescription Drug Monitoring Presented by: Len Abbott, Ph.D. Director Science and Technology Kathleen Valentine, General Manager PDM & Toxicology May 14,
Sarah Thompson, PharmD, CDOE Director of Clinical Services, Coastal Medical.
Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.
A System to Manage Long Term Opioid Prescribing in the Primary Care Setting Joy Nassar, MD University Medicine Foundation November 16, 2015.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Pennsylvania's Prescription Drug Monitoring Program (PDMP) May 17, 2016.
CDC Guideline for Prescribing Opioids for Chronic Pain- United States-2016 Gisele J. Girault, M.D. First Choice Healthcare Columbia, SC.
Oregon Prescription Drug Monitoring Program
Medication Assisted Treatment
Comparison of Opioid Prescribing Guidelines Violations by Clinical Speciality Chia-Chen Teng1,2, Christy Porusnik3, Erin Johnson4, Robert Rolfs3, Jonathan.
Wireless Access SSID: cwag2017
Gaston County Opioid Data
OPIOID EPIDEMIC.
Opioid Prescribing CAPT Thomas Weiser, MD, MPH Medical Epidemiologist
Opioid Addiction in Tennessee
AN UPDATE FROM THE OFFICE OF THE MEDICAL DIRECTOR
Medication-Assisted Therapy at Coleman Profession Services
Caldwell County Narcotic Initiative
Understanding the Opioid Epidemic
Opioids – A Pharmaceutical Perspective on Prescription Drugs
OPIOID SAFETY. Indiana Statistics In Summary… About 100 Hoosiers die from drug overdoses every month, many from opioids such as heroin and prescription.
ROOM project Addressing the Opioid Epidemic in the U.P.
Opioid Prescribing & Monitoring
Complete a legally valid prescription.
Controlled substance compliance
Barbara Allison-Bryan, MD
2017 Opioid Prescriber Survey Preliminary Results
PMP Advisory Committee
Prescription Drug Monitoring Program
2019 Medicare Part D Rule Opioid-related Provisions
Prescription Drug Monitoring Program
National Credentialing Forum 2019 San Diego, CA February
PMP Advisory Committee
Prescriptive Authority for Nurse-Midwives in Georgia
Strategic Initiatives to Address Opioid Overdose & Addiction
Data Sources ADH: Other AR Data: National: Vital Statistics PDMP
OSU Controlled Substances Training Module for Researchers
Presentation transcript:

TNSAM Addiction Medicine

Data source: Tennessee Department of Health, Office of Health Statistics, Death Statistical System. Overdose deaths were defined as having underlying cause of death ICD-10 codes X40-X44 (accidental), X60-X64 (intentional suicide), X85 (intentional homicide), and Y10-Y14 (undetermined).

Nearly 1.2 million Note: Figures include cases in which medications were combined with other drugs. Source: “Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Add Dispensing Restrictions for Buprenorphine Combination as used Medications,” Department of Health and Human Services, Federal Register, December 6, DrugED Visits Oxycodone146,535 Hydrocodone95,972 Methadone65,945 Fentanyl21,196 Hydromorphone17,666 Buprenorphine15,778

NAS Incidence by county, CY 2010

A.Mandatory Sign-up Pharmacy and Prescribers B.Query Database C.Pharmacies filled D.Data – 7 days to real time E.Method of Payment

 Board of Medical Examiners  Board of Nursing  Board of Pharmacy  Board of Osteopathic Examination  Board of Medical Examiners’ Committee on Physician Assistants  Board of Veterinary Medical Examiners  Board of Optometry  Board of Podiatric Medical Examiners  Board of Dentistry

Rules & Regulations 1.Establishing, Maintaining operating database 2.Access to database 3.Control dissemination of data and information 4.Sharing information with other states

 Active Licenses in January, 2013  21,019  With a TN mailing address  15,907  With a TN practice address  11,928

 Physician Assistants  1,424  OPA License  24

 Active Registered Nurses License  86,480  Advance Practice Nurses License  9,273  LPN License  30,068

 Pharmacies Active Licenses  2,368  Pharmacists Active Licenses  10,266

User Types8/12/2013 Increase from 8/05/2013 – 8/12/ /19/2013 Increase from 8/12/2013– 8/19/2013 Practitioner21, ,14244 Pharmacist6,309306,33122 Resident/Fellow1,871121,8754 Health Care Extender – Practitioner 2,981132,99312 Health Care Extender – Pharmacist Other Users (Admin, TennCare)

BUSINESS ACTIVITY SUB CODEDESCRIPTIONTN A0RETAIL PHARMACY737 A1CENTRAL FILL PHARMACY10 A3CHAIN PHARMACY908 A5ONLINE RETAIL PHARMACY0 A6ONLINE CENTRAL FILL PHARMACY0 A7ONLINE CHAIN PHARMACY0 B0HOSPITAL/CLINIC229 B1CHAIN HOSPITAL/CLINIC0 C0PRACTITIONER20,928 C1PRACTITIONER-DW/30268 C 2PRACTITIONER-MILITARY1 C3MLP-MILITARY0 C4PRACTITIONER-DW/ C5MILITARY PRACTITIONER – DW300 D0TEACHING INSTITUTION8 MAMLP-NURSE PRACTITIONER5,455 MBMLP-OPTOMETRIST831 MCMLP-PHYSICIAN ASSISTANT1,208 MDMLP-REGISTERED PHARMACIST0 DEA Numbers in TN

Number of Prescribers and Dispensers with Database Access and Actual Number Checking Data

Greater than 40 equivalents risks increase Greater than 100 equivalents 8-9 increase risk overdose

 Provider shoppers  > 4 providers in a year  Pharmacy shoppers  > 4 pharmacies in a year  High-dosage patients  > 100 morphine milligram equivalents (MME) per day average for year

37.1 million Opioid Prescription 5.2 million Patients 20,489 Provides 2419 Pharmacies 2011 TN Population 6.4 million

Risk of Unintentional Opioid-related Overdose Death by Patient Risk Factors Risk factorCases N=592 No. (%) Controls N=11,840 No. (%) AORs95% Confidence Interval Provider shopping 227 (38)513 ( 4 )5.13.2–8.1 Pharmacy shopping 145 (24)196 ( 2 )4.52.5–8.1 High dosage use 140 (24)172 ( 1 ) –20.8

 >90 days  II-IV Control Substances  Agreement Patient and Provider (No Restrictions)  Substance Abuse Risk  Urine Screens  2 year cycle renewal  Owner no criminal record or disciplinary actions related to controlled substances  Medical Director (Onsite 25% over all protocols have a substitute)  Policy and Procedure  Documentation TRG, Licensure  Certified Staff  Drug screen policy  Substance abuse Risk Tool  Q & A  Medicine Count  Patient Agreements

 Policy and Procedure (continued)  CSMD  Documents of request other providers  Infection Control  Policy Health and Safety  Safety STD  Policy for Continue of Care  Medical Records and Patient Billing  H & P Testing  Evaluations and Consults  Prescriptions objective and options  Risks vs Benefits  Log of Meds Rx  Instruction and Agreements  Periodic Reviews  Reason for Rx >72h of non malignant pain  CSMD  Records of other providers  Urine Q6 months and PRN  Records must be kept for 7 years  Payment  Must be check or credit card  Cash only for co-payment with insurance

 Chronic Pain Guidelines written by January 1, 2014  All prescribers with DEA 2 hours CME every 2 years  Prescribe 30 days at a time Schedule II-IV

By January 1, 2014 the commissioner shall develop recommended treatment guidelines for prescribing opioids, benzodiazepines, barbiturates, and carisoprodol. That can be used in the state as guide for caring for patients.

Introduction - Before initiating chronic opioid therapy (over ?? days) Screening (including TN risk model), non- opioid therapies, referral to MH, others Informed consent Women's special considerations Initiating chronic opioid therapy - Standard therapy, combination therapy Special considerations Methadone/suboxone UDS - qualitative & quantitative CSMD Documentation in decision making Follow up of therapy - UDS - qualitative & quantitative CSMD ED visits for OD What constitutes a failure of standard therapy? Referral to pain specialist Taper / discontinuation of opioids Documentation of decision making  Appendices  Screening tools  Follow up assessment tools  Pregnant women / NAS  Worker's comp  Tapering protocol  Informed consent  Sample pain contract  Proper disposal  Morphine equivalents calculator  Pediatric population special considerations  TN risk model for OD deaths  Doctor shopper risk factors  CSMD  Pharmacy Violence  Opioids short acting/long acting  Urine Drug Screens

Annual top 50 prescribers  Registered letter  Significant control substances  Number of patients  Morphine Equivalents prescribed  Department may withhold information if active case in BIV or OGC

Prescriber must respond with an explanation justifying the amounts of control substance prescribe within 15 business days.

Mitchell Mutter, MD Medical Director for Special Projects Tennessee Department of Health